Cardiac functional stress imaging: A sequential approach with stress echo and cardiovascular magnetic resonance

Starting January 2003, from the data bank of the Institute of Clinical Physiology, 143 (101 males; 64 ± 9 years) non-consecutive in-hospital patients or outpatients referred to the stress echocardiography laboratory for evaluation of chest pain, or patients with known coronary artery disease, or both were enrolled in the study. Exclusion criteria were congestive heart failure, unstable angina, documented cardiomyopathy and previous myocardial infarction. All patients underwent quantitative coronary angiography independently of test result and within 1 week of testing. Of the initial population of 152 who were referred for stress echocardiography (exercise in 110 and dipyridamole in 42), 3 had a poor acoustic window, 1 had an ambiguous response, 29 had a submaximal exercise stress echo test, and in 4 dipyridamole was prematurely interrupted due to side effects (Fig. 1). Four patients who experienced side effects during dipyridamole stress echocardiography were referred to dobutamine stress echocardiography. The remaining 35 patients were referred to the magnetic resonance laboratory to undergo dipyridamole CMR stress test. Of them 1 did not fit into MR bore and 1 was not imaged because of claustrophobic reaction. The study was approved by the Institutional review board. The final patient population consisted of 143 patients who were included in the accuracy analysis. The pretest likelihood of coronary artery disease was estimated from age, sex and symptoms [17]; patients with known coronary artery disease were assigned a value of 100%. The estimated likelihood of coronary artery disease was less than 50% in 9 patients (6%), 50% to 80% in 43 patients (30%), and greater than 80% in 91 patients (64%). According to individuals needs and physician's choices, 84 patients were evaluated after anti-anginal drugs had been discontinued, and 59 patients were evaluated during anti-anginal treatment (nitrates and/or calcium antagonists and/or beta-blockers). All patients gave their written informed consent when they underwent stress echocardiography. When patients signed the written informed consent they also authorized physicians to use their clinical data. Stress echo and CMR data were collected and analysed by physicians not involved in patient care.

Two-dimensional echocardiography and 12-lead electrocardiographic (ECG) monitoring were performed in combination with high dose dipyridamole (up to 0.84 mg over 6 min) or with semi-supine exercise ECG in accordance to well established protocols [18‐20]. Cardiac magnetic resonance was performed in combination with high dose dipyridamole with the same dose used for stress echo [18, 19]. During the procedure, blood pressure and ECG were recorded each minute.

Two-dimensional echocardiographic monitoring was performed throughout and up to 5 min after the end of peak stress. Two-dimensional images were recorded at baseline and at the end of each step. Regional wall motion analysis was evaluated at baseline and at peak stress with a semiquantitative assessment of a wall motion score index (WMSI), with the 17 segment model of the left ventricle, each segment ranging from 1 = normal/hyperkinetic to 4 = dyskinetic, according to the recommendations of the American Heart Association and American Society of Echocardiography [21, 22]. WMSI was derived by dividing the sum of individual segment scores by the number of interpretable segments [18]. Test positivity was defined as the occurrence of at least one of the following conditions: 1) new dyssynergy in a region with normal rest function (i.e., normokinesia becoming hypokinesia, akinesia or dyskinesia) in at least two adjacent segments. Non-echocardiographic test end-points were the following: peak dipyridamole dose; 85% of target heart rate; achievement of conventional end-points (such as severe chest pain and/or diagnostic ST segment changes). The test was also stopped, in the absence of diagnostic endpoints, for one of the following reasons of constituting a submaximal, non-diagnostic test: intolerable symptoms; limiting asymptomatic side effects, consisting of: a) hypertension (systolic blood pressure >220 mmHg; diastolic blood pressure >120 mmHg); b) hypotension (relative or absolute): >30 mmHg fall of blood pressure; c) supraventricular arrhythmias: supraventricular tachycardia or atrial fibrillation; d) ventricular arrhythmias: ventricular tachycardia; frequent, polymorphous premature ventricular beats.

CMR has been performed on a whole body MR scanner (Signa Cvi, GE, USA), operating at 1.5T by using a dedicated cardiac 8 elements phased-array coil. CMR acquisition has been performed according to a standardized protocol. Cardiac images have been obtained using a breath-hold segmented gradient echo Steady State Free Precession (SSFP) electrocardiographic triggered sequences. The echo time was 1.7 ms; repetition time 4.0 ms; slice thickness 8 mm with no interslice gap; field of view from 320 to 380 mm; data matrix size 256 × 224; phase of field of view 0.75; trigger delay was minimum; and views per segment 8 to 12 according to heart rate; flip angle 45°. Thirty cine frames were obtained for each slice. Three short axes slices, respectively at basal, middle and distal levels and 4-, 2-, and 3-chamber views of the left ventricle (LV), have been used for calculating regional wall motion (WM). The basal middle and distal segments were defined in relation to the papillary muscles; basal segments were below and middle segments were above the appearance of papillary muscles; middle segments were in the presence of papillary muscles. The LV has been divided into a 17-segment model. WM has been semi quantitatively assessed as follows: 1 = normokinetic, 2 = hypokinetic, 3 = akinetic and 4 = dyskinetic [21]. A dipyridamole test has been considered to be positive for functional criteria when wall motion worsened in 2 contiguous myocardial segments. There were 2 experienced observers reading wall motion, who were blinded to each other and to angiographic results.

Coronary angiography in multiple views was performed according to the standard Judkins or Sones technique. At least five views (including two orthogonal views) were acquired for the left and at least two orthogonal views for the right coronary arteries, respectively. Additional appropriate projections were obtained in case of superimposition of side branches or foreshortening of the segment of interest. A vessel was considered to have significant obstruction if its diameter was narrowed by 50% with respect to the prestenosic segment. All stenotic segments were evaluated by an automated edge detection system providing the percent stenosis diameter.

Values are expressed as mean ± standard deviation. Proportions were compared by the chi-square statistic; a Fisher's exact test was used when appropriate. A p value <0.05 was considered statistically significant. Calculations of sensitivity, specificity and accuracy were performed according to standard definitions. The 95% CIs were calculated for each technique, and the individual intervals were compared. Differences between techniques were considered significant at the 0.05 level when 95% CI did not overlap.

Coronary angiography demonstrated absence or only non-significant coronary artery disease in 55 patients and significant coronary artery disease in 88: Of these 31 had one vessel disease, 33 two vessel and 24 three vessel disease; left main coronary artery disease was found in 4 patients.

Stress echocardiography was diagnostic in 110 patients. Three patients had a poor acoustic window (additional file 1), 1 had an ambiguous response, 29 had a submaximal exercise stress test, and in 4 dipyridamole was prematurely interrupted due to side effects and were referred to dobutamine stress echocardiography (fig. 1). Rest WMSI was 1.0 and peak WMSI was 1.2 ± 0.3. The test was positive in 60 (54.5%) (additional files 2 and 3). Diagnostic ECG changes and chest pain were present during the test in 43 (72%) and 26 (43%) patients of the 60 with a positive test result.

The subgroup of 35 patients with a non-diagnostic and/or suboptimal stress echocardiography underwent dipyridamole CMR. The test was feasible in 33 of them (1 did not fit into the MR bore and 1 was not imaged because of anxiety) (fig. 1). Rest WMSI was 1.0 and peak WMSI was 1.12 ± 0.2. The test was positive in 14 (42%) patients (additional files 4 and 5).

Significant coronary artery disease was present in 71 of the 110 who underwent stress echocardiography and in 17 of the 33 who underwent dipyridamole CMR. The number of interpretable and/or maximal tests and test sensitivity significantly increased, with only a negligible loss of specificity when the sequential model was applied (fig.2 and 3). In fact sensitivity for detecting CAD was 63% (95% CI 52% to 73%) for stress echo consecutive patients and increased to 76% (95% CI 66% to 84%) for the sequential model with stress CMR; specificity was 89% (95% CI 78% to 96%) and 87% for stress CMR (95% CI 75% to 94%), respectively. Accuracy was 73% for stress echo (95% CI 65% to 80%) and increased to 80% (95% CI 73% to 86%) when stress CMR was employed.

The results of our study are broadly consistent with several studies suggesting that both stress echo (with exercise or pharmacologic stress, both with dipyridamole and dobutamine) and CMR are excellent options for the diagnosis of CAD [23‐27]. This has also been stated in recent ESC guidelines [2] and is in agreement with the recent ESC panel report on the clinical use of CMR that consider stress MR a class II examination for the diagnosis of coronary artery disease [28]. Overall, the feasibility and diagnostic accuracy of each test is lower than previously reported, but this is unavoidable when one moves from initial feasibility studies [15, 26, 29‐31] to clinical studies where the technique is deployed in the field on consecutive, challenging and often "difficult" patients [8]. The low sensitivity of the test may be due to several factors: All patients had a normal baseline function; a high number of patients were studied under anti-ischemic therapy (59 out of 152), which reduces sensitivity of wall motion; 31 out of 88 patients had a single vessel disease; Moreover we analysed only regional wall motion for both SE and CMR, without addition of myocardial perfusion or Coronary flow reserve criteria. Nevertheless, the overall performance of the algorithm seemed acceptable in the "real life" context.

There are several tests and strategies for the evaluation of patients with known or suspected coronary artery disease, but no single strategy has been demonstrated to be superior overall. The clinical plausibility of this algorithm stems from the obvious fact that "nobody is perfect", also among stress tests, and there is the primary need to optimise economic and technological resources without reducing the standard of diagnostic excellence. In the present study a clinical practical algorithm in which stress echocardiography and stress CMR can be used in a sequential way (see fig.1) for the assessment of CAD is proposed. The 3 major aspects of the algorithm are: 1. restrict the indication to more expensive methods to patients really in need; 2 – to have a maximal result in all patients, since submaximal stress test have low diagnostic and prognostic value [19, 32]; 3 – minimize long term risks due to the use of radiation [33, 34] with a radiation-free stress imaging algorithm allowing to select for coronary angiography and revascularization only patients with a functionally significant, and therefore prognostically malignant, forms of coronary artery disease, who are more likely to benefit from a physiologic driven revascularization. In this algorithm, CMR replaces cardiac stress scintigraphy which gives a dose exposure corresponding to 500 (with Sestamibi) to 1,600 (with Thallium or dual isotope scan) chest x-rays per each exam [33‐36]. Since 10 million cardiac stress scintigraphies are performed each year in US, the positive impact of our proposed algorhythm on downstream risks would be remarkable [37, 38]